Next-Generation Bispecific Nanobody Targeting CD5 and TNFRSF8 for Innovative T-Cell Lymphoma Therapy

VHH-P415 is a pioneering bispecific nanobody-based therapeutic program, specifically engineered to target CD5 molecule (CD5) and TNF receptor superfamily member 8 (TNFRSF8). Designed as a humanized single-domain antibody conjugate, VHH-P415 is currently undergoing Biological Testing and exhibits significant promise in the treatment of T-cell lymphoma. By simultaneously engaging both CD5 molecule (CD5) and TNF receptor superfamily member 8 (TNFRSF8), VHH-P415 aims to address critical disease mechanisms implicated in lymphoproliferative disorders. With its robust modality and target specificity, this candidate offers a differentiated strategy for the development of novel therapeutics in T-cell lymphoma management.

Licensing Opportunity

VHH-P415 is available for licensing and partnership opportunities. We welcome collaboration with industry leaders and research organizations interested in advancing bispecific nanobody therapeutics for hematologic malignancies.

Development Phase

Modality

VHH-P415 is an advanced bispecific single-domain antibody construct featuring two alpaca-derived nanobodies: one directed against CD30 and the other against CD5, joined by a flexible (G4S)4 linker. Further molecular engineering integrates a codon-optimized human granzyme b in tandem via a GS linker, with the complete construct efficiently expressed in Escherichia coli cells. The modular nanobody format, characterized by its compact size, high stability, and superior tissue penetration, is particularly advantageous for targeting malignant T cells within lymphoid tissues. This structure supports precise, efficient, and potentially deep tumor infiltration, enhancing targeted cytolytic activity in the context of T-cell lymphoma.

Target

CD5 and TNFRSF8 are critical immunological markers highly relevant to the pathophysiology of T-cell lymphoma. CD5 is a surface glycoprotein expressed predominantly on T lymphocytes and a subset of B cells, regulating T-cell receptor-mediated signaling and immune responses. TNFRSF8 is a member of the tumor necrosis factor receptor superfamily, most commonly associated with activated lymphocytes and certain malignant T-cell populations. Abnormal expression or activation of CD5 and TNFRSF8 is frequently implicated in T-cell lymphomagenesis and disease progression. Targeting both CD5 and TNFRSF8 with VHH-P415 offers a high-value strategic approach, enabling dual modulation of key oncogenic pathways and enhancing selective cytotoxicity against malignant cells while potentially reducing off-target effects in normal tissues. The dual-targeting modality may also address tumor heterogeneity and resistance mechanisms inherent to T-cell lymphoma.

Mechanism of Action

VHH-P415 is designed to bind simultaneously to CD5 and TNFRSF8 on the surface of malignant T cells, facilitating targeted modulation of key signal transduction pathways involved in T-cell lymphoma. The bispecific nanobody construct employs dual engagement to disrupt pathological signaling, leading to enhanced anti-tumor immune effector responses. The fusion of a human granzyme b moiety further augments direct cytolytic activity, promoting apoptosis in target cells upon internalization. This modality exemplifies the versatility of the nanobody platform, supporting innovation in antibody-drug conjugates (ADCs), bispecific antibody therapeutics, and other next-generation immune-modulating agents. The design of VHH-P415 thus extends the application potential of nanobody-based biologics in the treatment of complex hematologic malignancies.

T-cell Lymphoma

T-cell lymphoma encompasses a diverse group of hematologic malignancies originating from mature T lymphocytes, representing a challenging subset within non-Hodgkin lymphomas. Epidemiological surveys indicate that T-cell lymphomas account for a minority of overall lymphoma cases worldwide, yet they are characterized by aggressive clinical behavior, frequent relapse, and poor prognosis compared to B-cell counterparts. Standard-of-care treatments include combination chemotherapy regimens, radiotherapy, and, in select cases, hematopoietic stem cell transplantation. While targeted therapies have emerged, therapeutic efficacy remains limited by disease heterogeneity, high relapse rates, and significant adverse effects. There is thus an urgent need for more selective and potent targeted interventions. By exploiting the co-expression of CD5 and TNFRSF8 in T-cell lymphoma, VHH-P415 presents a novel mechanistic approach that could translate into improved clinical outcomes, reduced systemic toxicity, and the potential to overcome resistance observed with current options.